Promising Outcomes With Aflibercept for Diabetic Macular Edema: The PHOTON Trial
Researchers conducted a study to assess the effectiveness and safety of aflibercept at two...
Read More
Meeting Coverage
ASRS Satellite Symposia
The live and hybrid satellite symposia listed below will take place in conjunction with the Annual...
Read More
ASRS Awards
ASRS Founders Award Johanna M. Seddon, MD, ScM, FARVO, FASRS, professor, interim chair and...
Read More
ASRS Schedule At A Glance
Check out the ASRS Schedule! Friday, July 28 International Symposium 1:00-2:00 PM Sub-Specialty...
Read More
Highlights From AAN 2023 – MS
AAN 2023 MS Neurov1.indd
Read More
In MS, Healthcare Inequities Based on Race & Ethnicity “Still Prevail”
In MS, Black and Hispanic patients had more trouble accessing care and reported lower-quality care...
Read More
Curative-Intent Treatment Improves Survival in Early NSCLC Regardless of Race
Curative-intent therapy in patients with early non-small cell lung cancer resulted in “nearly...
Read More
Liver Transplant Outcomes Worse for Black Patients With HCC
While liver transplantation was less likely for Black patients with HCC, those who did receive a...
Read More
Demographics Impact Time to Treatment Initiation for Patients With HCC
Hepatocellular carcinoma (HCC) comprises 75% of all liver cancer diagnoses in the United...
Read More
Greater Benefit of Adjuvant Chemo Noted in High-Risk Patients With eNSCLC
For early-stage non-small cell lung cancer (eNSCLC) surgical resection with possible adjuvant...
Read More
Project Helps Improve Communication Between Clinicians & Patients With MS
“We saw a need to improve communication between patients and clinicians so that patients feel...
Read More
Highlights From AACR 2023
AACR 2023v4
Read More
KRAS Mutation Does Not Influence Atezolizumab Response in NSCLC
This retrospective analysis of the IMpower150 trial (NCT02486718) explored efficacy endpoints...
Read More
Adding Pembrolizumab to Perioperative Chemotherapy Improves Event-Free Survival in Early-Stage NSCLC
In KEYNOTE-671, neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant...
Read More
What Can Real-World Evidence Teach Us About Atezolizumab Plus Bevacizumab in HCC?
Therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients with...
Read More
IMbrave050: Adjuvant Atezolizumab Plus Bevacizumab Provides Landmark Recurrence-Free Survival for HCC
Adjuvant therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients...
Read More
Cortical Excitation/Inhibition Imbalance Has Predictive Value in MS
In MS, a lower cortical imbalance between excitation and inhibition may serve as a predictive...
Read More
Two Dietary Interventions Lead to Improvements in MS-Related Disability
It is recommended that neurologists discuss the benefits of improving diet quality with their...
Read More